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January 2013288 Abstractsrupture and aneurysm diameter relative to body size for men and women
with the goal of testing a novel method of rupture risk stratification that is
more appropriate for women.
Methods:We reviewed all patients in the Vascular Surgery Group of
New England database who underwent endovascular or open AAA
repair. We evaluated height, weight, body mass index (BMI), and body
surface area (BSA) as well as each of these values indexed to the aortic
diameter (eg, BSA index  aneurysm diameter (cm)/BSA [m2]). Along
with other relevant clinical variables, we constructed multivariable-ad-
justed logistic regression models using forward selection to determine
predictors of rupture repair vs elective repair. Models for men and women
were developed separately, and different models were compared using
the area under the curve (AUC).
Results:We identified 4045 patients who underwent AAA repair (11%
ruptured, 53% EVAR, 78% men). Women had significantly smaller diameter
aneurysms, lower BSA, and higher BSA indices than men (Table). For men,
the primary determinant of rupture was aneurysm diameter (AUC, 0.82):
55 mm (referent); 55-64 mm (OR, 0.9; 95% CI, 0.5-1.7; P  .771);
65-74 mm (OR, 3.9; 95% CI, 1.9-1.0; P .001); and75 mm (OR, 11.3;
95% CI, 4.9-25.8; P .001). In contrast, BSA index was most predictive of
rupture for women (AUC, 0.81), with higher odds of rupture at higher BSA
indices: 25 (OR, 3.9; 95% CI, 0.5-28.2; P  .175); 25-29 (OR, 3.3; 95%
CI, 0.8-14.5; P  .111); 30-34 (referent); 35-39 (OR, 6.4; 95% CI,
1.7-24.1; P  .006); and 40 (OR, 9.5; 95% CI, 2.3-39.4; P  .002). For
women, aneurysm diameter alone was not a significant predictor of rupture
after adjusting for BSA index.
Conclusions: Aneurysm diameter indexed to body size is the most
important determinant of rupture for women, whereas aneurysm diameter
alone is most predictive of rupture for men. Women with the largest
diameter aneurysms and the smallest body sizes are at the greatest risk of
rupture.
Table. Demographics and multivariable predictors of ruptured repair
Variables
Men
(n  3138)
Women
(n  907) P
Demographics
Age, mean (SD) years 71.9 (8.7) 74.3 (7.7) .001
Aneurysm diameter, mm .001
20-54, No. (%) 1032 (32.9) 368 (40.6)
55-64, No. (%) 1170 (37.3) 350 (38.6)
65-74, No. (%) 452 (14.4) 111 (12.2)
75, No. (%) 483 (15.4) 78 (8.6)
BSA, m2a .001
1.8, No. (%) 405 (12.9) 551 (60.7)
1.8-1.9, No. (%) 1073 (34.2) 258 (28.5)
2.0, No. (%) 1660 (52.9) 98 (10.8)
BSA index, cm/m2b .001
25, No. (%) 668 (21.3) 77 (8.5)
25-29, No. (%) 1136 (36.2) 231 (25.5)
30-34, No. (%) 678 (21.6) 297 (32.7)
35-39, No. (%) 342 (10.9) 171 (18.8)
40, No. (%) 314 (10.0) 132 (14.5)
Predictors of ruptured
repair OR (95% CI)c P OR (95% CI)d P
Aneurysm diameter, mm
20-54, % 1.0 1.0
55-64, % 0.9 (0.5-1.7) .8 1.1 (0.3-3.7) .85
65-74, % 3.9 (1.9-8.0) .01 3.3 (0.8-12.7) .09
75, % 11.3 (4.9-25.8) .01 3.2 (0.7-14.5) .13
BSA Index, cm/m2b
25, % 0.6 (0.3-1.4) .23 3.9 (0.5-28.2) .18
25-29, % 0.8 (0.5-1.5) .53 3.3 (0.8-14.5) .11
30-34, % 1.0 1.0
35-39, % 0.8 (0.5-1.4) .52 6.4 (1.7-24.1) .01
40, % 1.4 (0.8-2.6) .2 9.5 (2.3-39.4) .01
aBSA  BSA (m2)  0.20247  Height (m)0.725 Weight (kg)0.425.
bBSA index  aneurysm diameter (cm)/BSA (m2).
cArea under the curve  0.82.
dArea under the curve  0.81.
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FObjectives: Endovascular repair of abdominal aortic aneurysms (EVAR)
as become the first-line treatment of abdominal aortic aneurysms (AAA)
orldwide. Since the first successful EVAR in North America, the authors have
aintained a continuous, prospective database recording the details of each
rocedure.
Methods: Between 1992 and 2012, 1268 patients (mean age, 75 years;
5% men) underwent EVAR for repair of AAA. Fifteen different types of stent
rafts were used (Table). Eighty-one percent of patients exhibited high-risk
haracteristics that would preclude participation in Food andDrug Administra-
ion-mandated, industry sponsored-IDE pivotal trials. Ninety-three percent of
atients had at least one severe comorbid medical condition, with an average of
.2 conditions per patient. During EVAR, 38% had concomitant treatment
f associated common iliac artery aneurysms.Mean follow-up was 38.2 months.
Results: Major perioperative complications occurred in 7.5%, with a
erioperative mortality rate of 2.5%. Aneurysm size remained stable or
ecreased (5 mm) in 86.5% of patients and increased (5 mm) in 13.5%;
edian time to aneurysm expansion was 8.2 years. During follow-up, type I
ndoleak occurred in 2.1% of patients and type III in 0.2%. Reintervention
as required in 21% of patients.Mean time to reintervention was 26months.
reedom from aneurysm-related mortality was 91.1% at 12 years. Median
urvival for all-cause mortality was 5.6 years.
Conclusions: Progressive advances in EVAR allow safe, effective, and
urable repair of AAA, extending the instructions for use parameters of
ommercially available devices.
able 1. Operative data
Mean SD
nesthesia time (hours) 5.05  1.51
urgery time (hours) 3.70  1.47
stimated blood loss (mL) 367.8  515.3
ransfusion volume (mL) 645.3  647.4
ength of hospitalization (days) 2.75  5.96
nitial aneurysm size (cm) 5.9  1.2
neurysm size at latest F/U (cm) 5.5  1.6
No. of patients %
re-operative adjunctive procedure(s) 438 34.6%
atients receiving transfusion 181 14.3%
eneral anesthesia 75 5.9%
pinal or epidural anesthesia 1085 85.8%
ube graft 59 4.7%
ifurcated graft 992 78.2%
orto-uni-iliac graft 207 16.3%
hysician-made EVSGs 109 8.6%
ndustry-made EVSGs 1159 91.4%
ischarge on postoperative day 0 or 1 802 63.4%
ajor perioperative complications 95 7.5%
erioperative mortality 32 2.5%
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Objectives: Percutaneous transluminal angioplasty and stenting of the
liac veins is becoming a more common method of treating patients with
ymptomatic lower extremity venous outflow obstruction. Several questions
bout the conformation of these stents remain to be answered. One, in
articular, is whether these venous stents should extend into the vena cava or
top short of this in fear of causing further harm to the patient’s contralateral
eg.
Methods: We retrospectively reviewed prospectively collected data
rom 2008 to 2012 in patients with symptomatic iliocaval venous thrombo-
is who underwent percutaneous angioplasty and stenting. Data were col-
ected using the AVF venous stent database variables. Most patients were
aintained on full anticoagulation using warfarin (international normalized
atio 2-3) or low-molecular-weight heparin (weight-based daily or b.i.d.
osing). Patients with first time deep venous thrombosis were anticoagu-
ated for 6 months on average, and those with repeat deep venous throm-
osis were maintained on lifelong anticoagulation. Intraoperative anticoag-
lation was performed using intravenous heparin. Contralateral thrombosis
nd patency rates were recorded.
Results: A total of 183 iliocaval stents were placed in 66 patients
median age, 43; range 15-80 years), of which 63 patients experienced
hrombosis causing the venous outflow obstruction. Thirty patients experi-
nced acute venous thrombosis, 25 chronic, and nine acute on chronic.
orty-eight of 66 patients (72.7%) had patent stents noted on duplex
